Citigroup

Stevanato Group Announces Closing of Upsized Public Offering of Ordinary Shares and Exercise in Full of the Underwriters’ Option to Purchase Additional Ordinary Shares

Retrieved on: 
Tuesday, March 26, 2024
Medical Supplies, Health, Medical Devices, Other Health, General Health, Pharmaceutical, Biotechnology, Citigroup, BofA Securities, Exercise, Offering, Form, Telephone, Stevanato Group, William Blair & Company, Sale, Attention, Security (finance), Prospectus, Morgan Stanley, KeyBank, Varick Street, 2nd Floor

Stevanato Group sold 7,302,500 ordinary shares (the “Company Offering”), and Stevanato Holding S.r.l., an affiliate and major shareholder of the Company (the “Selling Shareholder”), sold 7,302,500 ordinary shares (the “Selling Shareholder Offering” and, together with the Company Offering, the “Offering”).

Key Points: 
  • Stevanato Group sold 7,302,500 ordinary shares (the “Company Offering”), and Stevanato Holding S.r.l., an affiliate and major shareholder of the Company (the “Selling Shareholder”), sold 7,302,500 ordinary shares (the “Selling Shareholder Offering” and, together with the Company Offering, the “Offering”).
  • The total gross proceeds from the Offering, before deducting underwriting discounts and commissions and offering expenses, were approximately $379.7 million, or approximately $189.8 million from each of the Company Offering and the Selling Shareholder Offering.
  • Stevanato Group will not receive any proceeds from the Selling Shareholder Offering.
  • Morgan Stanley and William Blair served as lead book-running managers and as representatives of the underwriters for the Offering.

Glean Appoints Tamar Yehoshua as President, Product and Technology to Accelerate Delivery of Enterprise AI Platform

Retrieved on: 
Tuesday, March 26, 2024
Software, Data Analytics, Artificial Intelligence, Data Management, Professional Services, Technology, Apps, Applications, Security, Microsoft, Organization, Pressure, Documentation, Citigroup, Software as a service, Growth, Data science, RAG, Knowledge, Meta, Research, Blog, Slack, ICONIQ, Lightspeed Venture Partners, Love, Ecosystem, Uber, IVP, Sequoia Capital, Sales

Glean , the AI-powered work assistant making waves among CIOs under pressure to quickly and securely deploy generative AI in the enterprise, announced Tamar Yehoshua as the company’s first President of Product and Technology, effective March 11.

Key Points: 
  • Glean , the AI-powered work assistant making waves among CIOs under pressure to quickly and securely deploy generative AI in the enterprise, announced Tamar Yehoshua as the company’s first President of Product and Technology, effective March 11.
  • She will oversee all of research and development, including global engineering, product, design, and data science, as Glean enters a period of rapid growth.
  • “Glean has seen tremendous growth over the last year as we help more and more companies bring secure, responsible generative AI into their organizations,” said Arvind Jain, co-founder and CEO of Glean.
  • “I loved working in venture capital, but the opportunity to lead product and technology at Glean was too good to pass up,” said Tamar Yehoshua.

Galderma Announces Full Exercise of Over-Allotment Option

Retrieved on: 
Tuesday, March 26, 2024
Cosmetics, Retail, Pharmaceutical, Health, BofA Securities, Citigroup, Exercise, COMMUNICATION, UBS, Sunlight, ADIA, Goldman Sachs, IPO, AMERICA, Morgan Stanley, BNP Paribas, EQT, Jefferies, CHF, NOT, Calendar, SIX, Security (finance)

Galderma Group AG (the “Company” or “Galderma”), the pure-play dermatology category leader, today announces that the Joint Global Coordinators exercised in full their option to purchase an additional 5,626,592 shares from Sunshine SwissCo AG (EQT), a wholly owned subsidiary of the Abu Dhabi Investment Authority (ADIA) and Auba Investment Pte.

Key Points: 
  • Galderma Group AG (the “Company” or “Galderma”), the pure-play dermatology category leader, today announces that the Joint Global Coordinators exercised in full their option to purchase an additional 5,626,592 shares from Sunshine SwissCo AG (EQT), a wholly owned subsidiary of the Abu Dhabi Investment Authority (ADIA) and Auba Investment Pte.
  • Including the shares placed in connection with the over-allotment option, a total of 43,137,209 existing registered and newly issued registered shares have been sold in the IPO.
  • Following the full exercise of the over-allotment option, the free float as calculated by SIX is expected to increase from 20.4% to 22.8%.
  • Goldman Sachs International, Morgan Stanley and UBS acted as Joint Global Coordinators and Joint Bookrunners for the IPO.

Tvardi Therapeutics Appoints Sujal Shah as Chairman and Adds Shaheen Wirk to the Board of Directors

Retrieved on: 
Tuesday, March 26, 2024
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Citigroup, Rabin Medical Center, Biomedicine, Biomedical engineering, Partnership, Tiger Management, Business, Duke University, Duke University Hospital, NDA, Acquisition, Credit Suisse, University, MD Anderson Cancer Center, Therapy, Bangladesh Technical Education Board, STAT3, Pharmaceutical industry

Tvardi Therapeutics, Inc. (“Tvardi”), a privately held, clinical-stage biopharmaceutical company focused on the development of STAT3 inhibitors, announced that current Board of Directors member Sujal Shah has been appointed Chairman, and experienced healthcare investor Shaheen Wirk, M.D.

Key Points: 
  • Tvardi Therapeutics, Inc. (“Tvardi”), a privately held, clinical-stage biopharmaceutical company focused on the development of STAT3 inhibitors, announced that current Board of Directors member Sujal Shah has been appointed Chairman, and experienced healthcare investor Shaheen Wirk, M.D.
  • Formerly, Mr. Shah was a healthcare investment banker for global investment banks Citigroup and Credit Suisse.
  • Newly appointed board member Dr. Wirk has more than 20 years of investment experience in public and private life science companies.
  • “The appointment of Sujal as Chairman and the addition of Shaheen to Tvardi’s Board of Directors are instrumental to the success of Tvardi,” said Imran Alibhai, Ph.D., CEO of Tvardi.

Piper Sandler Bolsters Fixed Income Team with the Addition of Ryan Hallam

Retrieved on: 
Monday, March 25, 2024
Banking, Professional Services, Finance, Risk, Citigroup, State university system, CFA, Piper Sandler Companies

Piper Sandler Companies (NYSE: PIPR), a leading investment bank, is pleased to announce the hiring of Ryan Hallam as a managing director and co-head of high-yield trading on the fixed income team.

Key Points: 
  • Piper Sandler Companies (NYSE: PIPR), a leading investment bank, is pleased to announce the hiring of Ryan Hallam as a managing director and co-head of high-yield trading on the fixed income team.
  • “We are excited to welcome Ryan to the Piper Sandler platform.
  • He will immediately expand our coverage of institutional accounts, which is highly complementary to our public finance efforts,” said Jon Allen , head of fixed income trading and risk at Piper Sandler.
  • “We look forward to the positive impact Ryan will bring to the fixed income group.

Auna Announces Pricing of Initial Public Offering of US$360 Million (Gross Proceeds) of Class A Shares

Retrieved on: 
Friday, March 22, 2024
Managed Care, Hospitals, Health Insurance, Health, Citigroup, J. P. Morgan, Madison Avenue, Form, Telephone, Morgan Stanley, Sale, Lexington Avenue, Prospectus, BTG Pactual, HSBC, Varick Street, 2nd Floor, J.P. Morgan & Co., Security (finance)

Auna S.A. (“Auna”) a Latin American healthcare company with operations in Mexico, Peru and Colombia, today announced that it has priced its initial public offering of 30,000,000 class A ordinary shares (“class A shares”), at a price of US$12.00 per class A share.

Key Points: 
  • Auna S.A. (“Auna”) a Latin American healthcare company with operations in Mexico, Peru and Colombia, today announced that it has priced its initial public offering of 30,000,000 class A ordinary shares (“class A shares”), at a price of US$12.00 per class A share.
  • The class A shares have been approved for listing on the New York Stock Exchange and will start trading on March 22, 2024 under the ticker symbol “AUNA”.
  • The offering is expected to settle on or about March 26, 2024, subject to customary closing conditions.
  • In connection with the offering, Auna has granted to the underwriters a 30-day option to purchase up to an additional 4,500,000 class A shares at the initial public offering price.

Stevanato Group Announces Pricing of Upsized Public Offering of Ordinary Shares

Retrieved on: 
Friday, March 22, 2024
Medical Supplies, Health, Medical Devices, Other Health, General Health, Pharmaceutical, Biotechnology, Citigroup, BofA Securities, Exercise, Offering, Form, Telephone, Stevanato Group, William Blair & Company, Sale, Attention, Security (finance), Prospectus, Morgan Stanley, KeyBank, Varick Street, 2nd Floor

Stevanato Group S.p.A. (NYSE: STVN) (“Stevanato Group,” or the “Company”), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, today announced the pricing of its upsized underwritten public offering of an aggregate of 12,700,000 of its ordinary shares at a public offering price of $26.00 per share.

Key Points: 
  • Stevanato Group S.p.A. (NYSE: STVN) (“Stevanato Group,” or the “Company”), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, today announced the pricing of its upsized underwritten public offering of an aggregate of 12,700,000 of its ordinary shares at a public offering price of $26.00 per share.
  • Stevanato Group is offering 6,350,000 ordinary shares (the “Company Offering”), and Stevanato Holding S.r.l., an affiliate and major shareholder of the Company (the “Selling Shareholder”), which currently holds approximately 78% of Stevanato Group’s outstanding ordinary shares, is offering 6,350,000 ordinary shares (the “Selling Shareholder Offering” and, together with the Company Offering, the “Offering”).
  • Stevanato Group and the Selling Shareholder have granted the underwriters an option, exercisable for 30 days after the date of the final prospectus supplement, to purchase up to 1,905,000 additional ordinary shares on the same terms and conditions.
  • Stevanato Group will not receive any proceeds from the Selling Shareholder Offering.

Reddit Announces Pricing of Initial Public Offering

Retrieved on: 
Wednesday, March 20, 2024
Media, Communications, Social Media, Citigroup, BofA Securities, JMP, J. P. Morgan, Goldman Sachs, Telephone, Sale, Attention, Security (finance), Prospectus, Bank of America, Broadridge Financial Solutions, MUFG, Varick Street, Deutsche Bank

Reddit, Inc. (“Reddit”) today announced the pricing of its initial public offering of an aggregate 22,000,000 shares of its Class A common stock, 15,276,527 of which are being sold by Reddit and 6,723,473 of which are being sold by certain selling stockholders, at a public offering price of $34 per share.

Key Points: 
  • Reddit, Inc. (“Reddit”) today announced the pricing of its initial public offering of an aggregate 22,000,000 shares of its Class A common stock, 15,276,527 of which are being sold by Reddit and 6,723,473 of which are being sold by certain selling stockholders, at a public offering price of $34 per share.
  • Reddit will not receive any proceeds from any sale of shares by the selling stockholders.
  • In addition, Reddit has granted the underwriters a 30-day option to purchase up to an additional 3,300,000 shares of its Class A common stock at the initial public offering price, less underwriting discounts and commissions.
  • Morgan Stanley & Co. LLC, Goldman Sachs & Co. LLC, J.P. Morgan, and BofA Securities are acting as lead book-running managers for the offering.

Paystand Named Winner of Fintech Breakthrough Award for DeFi Innovation

Retrieved on: 
Wednesday, March 20, 2024
Banking, Software, Networks, Professional Services, Internet, Blockchain, Fintech, Data Management, Payments, Apps, Applications, Technology, Security, Finance, Spend, Bitcoin, Ethereum, Mastercard, Organization, Citigroup, J. P. Morgan, Network, SVB, Education, JPMorgan Chase, Coinbase, Death, Insurance, Life, DSO, Silicon, Decentralized finance, CSR, Silicon Valley Bank, Movement, Cryptocurrency

Paystand , the global leader in blockchain-enabled B2B payments, today announced it has won the DeFi Innovation category in the 2024 Fintech Breakthrough Awards.

Key Points: 
  • Paystand , the global leader in blockchain-enabled B2B payments, today announced it has won the DeFi Innovation category in the 2024 Fintech Breakthrough Awards.
  • Paystand has been honored as one of the ‘breakthrough’ innovators in the fintech market today.
  • Notable companies also named as fintech winners include Coinbase, J.P. Morgan Chase, Mastercard, Citi, Experian, and more.
  • The award recognizes Paystand for its decentralized finance technology, including:
    The Paystand Network , which allows every Paystand customer as well as their payers (more than 800,000), to leverage the blockchain-enabled network for fast, secure and zero-transaction fees money movement.

Bristol Myers Squibb Completes Acquisition of Karuna Therapeutics, Strengthening Neuroscience Portfolio

Retrieved on: 
Monday, March 18, 2024
Mental Health, Health, Neurology, Clinical Trials, Pharmaceutical, Biotechnology, BMY, Psychosis, Bristol Myers Squibb, Citigroup, Growth, Schizophrenia, Goldman Sachs, KarXT, EPS, Patient, Simpson Thacher & Bartlett, Acquisition, BMS, LLP, Therapy, GAAP, Covington & Burling, Bipolar I disorder, PDUFA, Pharmaceutical industry

Bristol Myers Squibb (NYSE: BMY) today announced that it has successfully completed its acquisition of Karuna Therapeutics, Inc. (“Karuna”).

Key Points: 
  • Bristol Myers Squibb (NYSE: BMY) today announced that it has successfully completed its acquisition of Karuna Therapeutics, Inc. (“Karuna”).
  • With the acquisition's completion, Karuna shares have ceased trading on the Nasdaq Global Select Market and Karuna is now a wholly owned subsidiary of Bristol Myers Squibb (“BMS”).
  • “We are excited to expand our neuroscience portfolio as we welcome Karuna to Bristol Myers Squibb,” said Chris Boerner, Ph.D., Chief Executive Officer, Bristol Myers Squibb.
  • Bristol Myers Squibb expects to offset the operational expenses of the transaction through continued disciplined resource allocation, cost efficiencies and portfolio prioritization.